| | Class 2 Device Recall Instrumentation Laboratory GEM Premier 4000 |  |
| Date Initiated by Firm | February 14, 2011 |
| Date Posted | May 10, 2011 |
| Recall Status1 |
Terminated 3 on May 23, 2012 |
| Recall Number | Z-2165-2011 |
| Recall Event ID |
58060 |
| 510(K)Number | K093623 |
| Product Classification |
Glucose, oxidase, glucose - Product Code CGA
|
| Product | Instrumentation Laboratory GEM Premier 4000
PN 00025000000
The GEM Premier 4000 is a portable critical care system for use by health care professionals to rapidly analyze whole blood samples at the point of health care delivery in a clinical setting and in a central laboratory. The instrument provides quantitative measurements of pH, pC02, p02, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin and CO-OXimetry (tHb, 02Hb, COHb, MetHb, HHb) parameters. Total bilirubin can also be quantitated from heparinized plasma samples when analyzed in the tBili/CO-Ox mode. These parameters, along with derived parameters, aid in the diagnosis of a patient's acidlbase status, electrolyte and metabolite balance and oxygen delivery capacity. Total bilirubin measurements are used in the diagnosis and management of biliary tract obstructions, liver disease and various hemolytic diseases and disorders involving the metabolism of bilirubin. In neonates, the level of total bilirubin is used to aid in assessing the risk of kernicterus |
| Code Information |
Serial Numbers range: 06050100 -11024479 |
| FEI Number |
1217183
|
Recalling Firm/ Manufacturer |
Instrumentation Laboratory Co. 180 Hartwell Road Bedford MA 01730-2443
|
| For Additional Information Contact | 781-861-4467 |
Manufacturer Reason for Recall | Measurement (amperometric) spike can occur early in cartridge life on the glucose and lactate sensors during patient blood analysis, leading to erroneously high
results |
FDA Determined Cause 2 | Device Design |
| Action | Instrumentation Laboratory notified accounts by a Field Safety NotifIcation Letter dated Feb 2011. The letter identified the product, the problem, and the action to be taken by the customer. Customers were instructed to use whichever of the following mitigation options works best for their institution. Both options will have the same effect to eliminate the potential impact of a rare spike on the glucose and lactate sensors.
Customers were instructed to complete the enclosed Response Tracking Form and return immediately fax to 781-861-4207 or e-mail to ra-usa@ilww.com.
Customers were advised to contact their local representative with any questions. |
| Quantity in Commerce | 4379 units |
| Distribution | Worldwide Distribution - USA (nationwide) and the countries of CANADA ISRAEL ITALY APAN KUWAIT MALAYSIA MEXICO NETHERLANDS NORWAY PANAMA POLAND PORTUGAL PUERTO RICO SAUDI ARABIA SLOVENIA SPAIN SWEDEN SWITZERLAND TAIWAN TURKEY UNITED ARAB EMIRATES UNITED KINGDOM and URUGUAY. |
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
|
| 510(K) Database | 510(K)s with Product Code = CGA
|
|
|
|